The current standard of care for patients with hemophilia A is regular prophylaxis with factor VIII (FVIII) administered intravenously. Interest in subcutaneous (s.c.) administration, to potentially increase convenience, reduce the treatment burden and improve compliance, is increasing.
| INTRODUC TI ON
Coagulation factor VIII (FVIII) replacement therapy-particularly the introduction of recombinant FVIII (rFVIII) products in the 1990s-transformed the landscape of hemophilia A care. 1 The availability of prophylactic FVIII replacement therapy has reduced the incidence of hemophilic arthropathy and overall morbidity and turned a life-threatening disease into a chronic yet manageable condition. [2] [3] [4] [5] The life expectancy of people with hemophilia (PWH)
is now approaching that of the general population, 6 and new treatments are increasingly focused on reducing the burden of care. 7 The introduction of extended half-life (EHL) rFVIII therapies has increased bleed protection and FVIII trough levels, with potential for improved quality of life. 7 Furthermore, EHL rFVIII therapies have improved convenience of prophylaxis because of the lessfrequent dosing regimens required, compared with standard halflife products. However, the relative increase in half-life of currently available EHL FVIII products for hemophilia A treatment is only modest, compared with that of EHL factor IX (FIX) products used to treat hemophilia B. 7 All EHL products are currently administered intravenously. 7 Regular intravenous (i.v.) administration of rFVIII is challenging, particularly for young children and the elderly, due to restricted vascular access. 1, 7 An alternative to i.v. is subcutaneous (s.c.) administration, which has the potential to further improve the convenience of prophylaxis by reducing the need for i.v. access and central venous access devices (CVADs). 8 Furthermore, s.c. administration is less invasive and may be less painful than i.v. treatment due to the shorter and thinner injection needles used. 8, 9 Easier administration of rFVIII has the potential to increase adherence and, therefore, improve patient outcomes. 10 A major limitation of s.c. administration of unmodified FVIII is that its bioavailability is low in preclinical models, due to insufficient absorption and rapid degradation. [11] [12] [13] Consequently, its clinical application has not been successful. 9 Alternative subcutaneously administered hemophilia treatment options include bispecific antibodies that bridge activated FIX and factor X (eg, emicizumab) 14 or agents that inhibit endogenous anticoagulant pathways (eg, fitusiran and concizumab). 15 However, the safety and efficacy of these treatments outside of the clinical trial setting has not been established. 15 N8-GP (turoctocog alfa pegol; Novo Nordisk, Bagsvaerd, Denmark) is an EHL rFVIII approved in the United States for prophylaxis and treatment of bleeding episodes in patients with hemophilia A. 16, 17 In adults with severe hemophilia A, the plasma half-life of N8-GP following i.v. administration is approximately 19 hours, which equates to a 1.6-fold prolonged half-life compared with standard half-life rFVIII. 18 N8-GP is manufactured by glycoPEGylation of turoctocog alfa, whereby the terminal sialic acid on an O-glycan in the truncated B-domain is replaced by a conjugated sialic acid containing a 40-kDa polyethylene glycol (PEG) moiety. 16 Clinical trials have shown that i.v. N8-GP is efficacious and well tolerated in previously treated patients (PTPs), with a low incidence of inhibitors reported. [19] [20] [21] The two major challenges of s.c. administration of large-protein pharmaceuticals are immunogenicity and bioavailability of the drug to achieve therapeutic levels. 22 The development of high-affinity immunoglobulin G (IgG) anti-FVIII antibodies to exogenous FVIII remains the most serious complication of hemophilia A management. 23 Inhibitors neutralize FVIII, resulting in ineffective FVIII replacement therapy and poor bleed control. 23, 24 Preclinical studies suggest that coagulation factor proteins administered subcutaneously are, potentially, more immunogenic than those administered intravenously; 25 however, the immunogenicity of FVIII in humans following s.c. administration is unknown.
Preclinical studies have shown s.c. N8-GP, in contrast to s.c. standard half-life FVIII, to have a bioavailability of 24% and 26% and a half-life of 14 and 15 hours in hemophilia A mice and cynomolgus monkeys, respectively. 9 Compared with standard half-life rFVIII, gly-coPEGylation appears to increase the bioavailability of s.c. N8-GP and also may be responsible for increasing the solubility of N8-GP under isotonic conditions. 9 Based on preclinical pharmacokinetic (PK) data, s.c. N8-GP daily was predicted to provide FVIII trough levels of 2.5-10% in adults, which would convert severe hemophilia patients to a moderate or potentially even mild phenotype. 9 Here, we present results from the alleviate 1 trial, the first-inhuman clinical trial to investigate s.c. N8-GP for prophylactic use in patients with severe hemophilia A. Its aim was to evaluate the PK, immunogenicity, safety, and preliminary efficacy following single and multiple doses of s.c. N8-GP in PTPs.
| MATERIAL S AND ME THODS

| Trial design and treatments
Alleviate 1 was a phase 1, multicenter, PK, safety and preliminary efficacy trial in PTPs with severe hemophilia A conducted in 25 sites in 9 countries (Austria, Bulgaria, France, Germany, Japan, Serbia, Turkey, United Kingdom, and United States). The primary objective was to assess the safety of s.c. N8-GP, including immunogenicity.
The trial was approved by all relevant independent ethics committees and institutional review boards. Written informed consent was obtained from all participants or their legally authorized
Essentials
• Subcutaneous (s.c.) factor VIII (FVIII) administration may reduce the treatment burden of hemophilia A.
• Alleviate 1 investigated the s.c. administration of turoctocog alfa pegol (N8-GP) in adults.
• Steady-state FVIII activity levels of ~10% suggest a potential for efficacious s.c. FVIII prophylaxis.
• Five out of 26 patients developed anti-N8-GP binding antibodies, one of whom developed inhibitors to FVIII.
representatives before any trial-related activities commenced. The trial was conducted in accordance with the declaration of Helsinki 26 and Good Clinical Practice 27 , and is registered at www.clini caltr ials. gov (alleviate 1 NCT02994407).
The trial consisted of two parts. Part A was a single-dose dose-escalation trial and part B was a multiple-dose trial ( Figure 1 ). Figure 1 ). Population PK modelling was used to determine doses for part B that predicted 95% of patients would have a FVIII trough level of ≥3%. Patients <60 kg received 2000 IU (one injection) and patients ≥60 kg received 4000 IU (two injections) of s.c. N8-GP daily.
Participants in part
Patients in part A were allowed to enroll into part B. Dose adjustments in part B were permitted at the discretion of the investigator, based on FVIII trough levels (target trough level >3%) or bleeding criteria (≥1 spontaneous treatment-requiring bleed between Visit 4 and 8) and could take place any time between Visit 4 and 8, 2-13 weeks after the first dose of s.c. N8-GP. Dosing could be increased up to 6000 IU, but could not exceed 100 IU/kg/day. enrollment, as the first six patients had to be ≥18 years old. All participants were PTPs with >150 exposure days (EDs) to any FVIII product. Patients with a history of inhibitors or immune deficient patients due to HIV (defined as a CD4+ lymphocyte count ≤200/ µL or viral load ≥400 000 copies/mL) were not eligible for the trial. using the Nijmegen-modified Bethesda assay, including heat treatment of controls and samples. 28, 29 In accordance with the European Medicines Agency guideline, 30 
| Key eligibility criteria
| Objectives, endpoints and assessments
| Statistical methods
No formal sample size calculation was performed and data analyses were based on descriptive statistics. PK endpoints were based on the full analysis set, comprising all patients with a minimum of one evalu- 
| RE SULTS
| Subject disposition and baseline characteristics
Baseline characteristics for patients in parts A and B are shown in All patients who were dosed completed the trial (Figure 1 
| PK (parts A and B)
PK parameters are shown in Table 4 ). Overall, treatment with s.c. N8-GP in part B resulted in a mean pre-dose (trough) FVIII activity close to 10% throughout the 13-week study period ( Figure 2B ). 
| Immunogenicity and safety
| Efficacy (part B only)
Mean total monthly consumption of s.c. N8-GP was 1477. after multiple dosing is reached after 4 to 5 half-lives for a drug following linear kinetics 32, 33 and refers to the situation in which the overall absorption of a drug is in dynamic equilibrium with its elimination. 31 The half-life of s.c. N8-GP in humans was similar to that of i.v. N8-GP -21.6 versus approximately 19 hours, respectively. 20 As predicted from preclinical models, 9 daily treatment with s.c. N8-GP shifted most patients from a severe to mild hemophilia A phenotype, with mean FVIII activity >10% at all times and little fluctuation between trough and peak activity (Figures 2 and 4) . Converting the phenotype of severe hemophilia patients is a key goal of prophylaxis to improve patient outcomes over the long term. 34 The development of inhibitors remains the most significant complication of FVIII replacement therapy. 23 "Late" immunogenic responses have been reported previously in PTPs introduced to two i.v. FVIII products processed with a new manufacturing method. [36] [37] [38] After the introduction of this new pasteurized FVIII concentrate (FVIII CPS-P) in the Netherlands in 1990, an increase in the occurrence of inhibitors in previously treated hemophilia A patients was reported after 50-1000 EDs. 36, 37 Unlike the typical immunological response, these antibody titers showed a rapid decline following a switch to a different FVIII product. 37 The same was true following the introduction of FVIII-SDP (Octavi SDPlus, Octapharma, Lachen, Switzerland) in Belgium and Germany in the 1990s. 38, 39 In these cases, immunogenicity was likely due to a new viral inactivation step introduced in the manufacturing of the FVIII products. 38 exposure and >5 years of clinical exposure in PTPs. 18, 40 Only one PTP developed an inhibitor with i.v. N8-GP in these trials, [19] [20] [21] 41 which suggests that the immunogenicity results in alleviate 1 are likely due to the s.c. method of administration, since the N8-GP molecules are otherwise identical. Subcutaneous administration exposes high concentrations of N8-GP to different components of the immune system compared with i.v. administration. 42 Furthermore, the transport of the N8-GP molecule into the vascular space via the lymphatic system may impact its immunogenicity.
Preclinical studies suggest that coagulation factor proteins administered subcutaneously are, potentially, more immunogenic than those administered intravenously. Considerably higher binding antibody titer levels were observed in hemophilia A mice following administration of s.c. FVIII compared with i.v. FVIII. 25 However, in a preclinical trial in which tolerance was induced with i.v. rFVIII in humanized hemophilia A mice, tolerance was not broken by changing the route of administration from i.v. to s.c. 43 These positive preclinical data supported the investigation of s.c. N8-GP in humans; however, preclinical data are not necessarily applicable to humans.
A possible reason for the increased immunogenicity associated with the s.c. route of administration is that the skin is a highly effective immunological organ that continually recognizes and eliminates a range of antigens. 44 Human skin contains a range of professional antigen-presenting cells, as well as the largest reservoir of T-cells in the body necessary to mount an immunologic response. [44] [45] [46] The late immunological response could be due to the instability of FVIII in s.c. tissue or possibly due to delayed and/or inefficient epitope spreading. 25 The presence of high levels of anti-N8-GP binding antibodies correlated with declining FVIII activity in four patients. N8-GPspecific IgG4, which is known to correlate with inhibitor status, 47 was detected in four of the five patients with anti-N8-GP binding antibodies. AEs in part B were reported over a period of 6.46 patient-years of exposure; a longer duration of follow-up may have resulted in additional cases of antibody, or even inhibitor, development. Although it cannot be ruled out that a more sensitive assay would have detected a higher frequency of FVIII inhibitors, the incidence of clinically significant FVIII inhibitors in alleviate 1 was based on the threshold detection of ≥0.6 BU in accordance with World Federation of Hemophilia guidelines. 48 Nevertheless, the concern remained that these binding antibodies would have developed into FVIII inhibitors upon further exposure as indicated by the IgG maturation pattern and declining trough levels. Five patients developed anti-N8-GP antibodies in part B, four of whom tested positive for IgG4 antibodies. FVIII inhibitors were detected using the Nijmegen-modified Bethesda assay, including heat treatment of controls and samples. The presence of anti-N8-GP antibodies was determined by a validated radioimmunoassay and presence of antibodies confirmed in a confirmatory assay. Positive antibody samples were further characterized, eg, for immunoglobulin isotype and/or binding properties by a direct ELISA. +, inhibitor/antibodies detected; −, inhibitor/antibodies not detected. ELISA, enzyme-linked immunosorbent assay; FVIII, factor VIII; NR, not reported. 
